S-Adenosylmethionine,Silybin,Phospholipid Supplement

Verify with FDA CVM →

36 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
36
Total Reports
7
Deaths Reported
1940.0%
Death Rate

Active Ingredients

S-Adenosylmethionine,Silybin,Phospholipid Supplement

Administration Routes

UnknownOral

Species Affected

Dog 33
Cat 3

Most Affected Breeds

Pointing Dog - Hungarian Short-haired (Vizsla) 4
Retriever - Labrador 3
Spitz - German Pomeranian 3
Dachshund (unspecified) 2
Boxer (German Boxer) 2
Terrier - Jack Russell 2
Domestic Shorthair 2
Terrier (unspecified) 1
Chinese Crested Dog – Powder Puff with veil coat 1
Poodle - Standard 1

Most Reported Reactions

Vomiting 12
Elevated alanine aminotransferase (ALT) 9
Elevated serum alkaline phosphatase (ALP) 9
Diarrhoea 7
Lethargy (see also Central nervous system depression in Neurological) 6
Elevated liver enzymes NOS 6
Death by euthanasia 5
Elevated total bilirubin 4
Other abnormal test result NOS 4
Abnormal radiograph finding 3
Liver failure 3
Unclassifiable adverse event 3

Outcome Breakdown

Recovered/Normal
13 (36.1%)
Outcome Unknown
9 (25.0%)
Ongoing
7 (19.4%)
Euthanized
5 (13.9%)
Died
2 (5.6%)

Data Summary

Metric Value
Total adverse event reports 36
Reports involving death 7
Case-fatality rate (reported events) 1940.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

S-Adenosylmethionine,Silybin,Phospholipid Supplement Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 36 adverse event reports referencing S-Adenosylmethionine,Silybin,Phospholipid Supplement, including 7 reports in which the animal died — a 1940.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: S-Adenosylmethionine,Silybin,Phospholipid Supplement. Reported administration routes include Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in S-Adenosylmethionine,Silybin,Phospholipid Supplement reports are Dog (33 reports), Cat (3 reports), with Dog accounting for the largest share. Within those species, Pointing Dog - Hungarian Short-haired (Vizsla) (4), Retriever - Labrador (3), Spitz - German Pomeranian (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with S-Adenosylmethionine,Silybin,Phospholipid Supplement are Vomiting (12), Elevated alanine aminotransferase (ALT) (9), Elevated serum alkaline phosphatase (ALP) (9), Diarrhoea (7). Of the 36 reports with a coded outcome, Recovered/Normal is the leading category at 36.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on S-Adenosylmethionine,Silybin,Phospholipid Supplement.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial